FI20115367A0 - Menetelmä sydän- ja verisuonitapahtumien määrittämiseksi käyttämällä IGFBP-fragmentteja - Google Patents

Menetelmä sydän- ja verisuonitapahtumien määrittämiseksi käyttämällä IGFBP-fragmentteja

Info

Publication number
FI20115367A0
FI20115367A0 FI20115367A FI20115367A FI20115367A0 FI 20115367 A0 FI20115367 A0 FI 20115367A0 FI 20115367 A FI20115367 A FI 20115367A FI 20115367 A FI20115367 A FI 20115367A FI 20115367 A0 FI20115367 A0 FI 20115367A0
Authority
FI
Finland
Prior art keywords
igfbp
cardiovascular events
fragments
insulin
growth factor
Prior art date
Application number
FI20115367A
Other languages
English (en)
Swedish (sv)
Inventor
Alexey G Katrukha
Alexander B Postnikov
Tatiana I Solovyeva
Alexey V Kharitonov
Original Assignee
Hytest Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hytest Oy filed Critical Hytest Oy
Priority to FI20115367A priority Critical patent/FI20115367A0/fi
Publication of FI20115367A0 publication Critical patent/FI20115367A0/fi
Priority to PCT/FI2012/050365 priority patent/WO2012140327A1/en
Priority to EP12770850.1A priority patent/EP2697654B1/en
Priority to CN201280029310.5A priority patent/CN103703373A/zh
Priority to KR1020137030269A priority patent/KR20140030188A/ko
Priority to JP2014504367A priority patent/JP2014515824A/ja
Priority to US13/823,674 priority patent/US10191066B2/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1754—Insulin-like growth factor binding proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4745—Insulin-like growth factor binding protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
FI20115367A 2011-04-15 2011-04-15 Menetelmä sydän- ja verisuonitapahtumien määrittämiseksi käyttämällä IGFBP-fragmentteja FI20115367A0 (fi)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FI20115367A FI20115367A0 (fi) 2011-04-15 2011-04-15 Menetelmä sydän- ja verisuonitapahtumien määrittämiseksi käyttämällä IGFBP-fragmentteja
PCT/FI2012/050365 WO2012140327A1 (en) 2011-04-15 2012-04-13 Method for determining the risk of cardiovascular events using igfbp fragments
EP12770850.1A EP2697654B1 (en) 2011-04-15 2012-04-13 Method for determining the risk of cardiovascular events using igfbp fragments
CN201280029310.5A CN103703373A (zh) 2011-04-15 2012-04-13 利用igfbp片段确定心血管事件的风险的方法
KR1020137030269A KR20140030188A (ko) 2011-04-15 2012-04-13 Igfbp 단편을 이용한 심혈관 사건의 위험도 측정 방법
JP2014504367A JP2014515824A (ja) 2011-04-15 2012-04-13 Ｉｇｆｂｐ断片を用いた、循環器系事象の危険度の判定方法
US13/823,674 US10191066B2 (en) 2011-04-15 2012-04-13 Method for determining the risk of cardiovascular events using IGFBP fragments

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20115367A FI20115367A0 (fi) 2011-04-15 2011-04-15 Menetelmä sydän- ja verisuonitapahtumien määrittämiseksi käyttämällä IGFBP-fragmentteja

Publications (1)

Publication Number Publication Date
FI20115367A0 true FI20115367A0 (fi) 2011-04-15

Family

ID=43919687

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20115367A FI20115367A0 (fi) 2011-04-15 2011-04-15 Menetelmä sydän- ja verisuonitapahtumien määrittämiseksi käyttämällä IGFBP-fragmentteja

Country Status (7)

Country Link
US (1) US10191066B2 (fi)
EP (1) EP2697654B1 (fi)
JP (1) JP2014515824A (fi)
KR (1) KR20140030188A (fi)
CN (1) CN103703373A (fi)
FI (1) FI20115367A0 (fi)
WO (1) WO2012140327A1 (fi)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2719914C1 (ru) * 2019-12-06 2020-04-23 федеральное государственное бюджетное образовательное учреждение высшего образования "Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации Способ прогнозирования исходов операций коронарного шунтирования

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150090010A1 (en) * 2013-09-27 2015-04-02 Chang Gung University Method for diagnosing heart failure
KR102328327B1 (ko) 2014-09-26 2021-11-22 소마로직, 인크. 심혈관 위험 사건 예측 및 이의 용도
JP2017533428A (ja) * 2014-10-22 2017-11-09 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ バイオマーカー及び予測方法
CN110577589B (zh) * 2018-06-11 2023-04-14 朱伟东 胰岛素样生长因子结合蛋白4突变体及其制药用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115382B1 (en) * 1999-03-15 2006-10-03 Mayo Foundation For Medical Education And Research Method for detecting IGFBP-4 protease without detecting IGFBP-4 protease/proMBP Complex
US6500630B2 (en) 2001-01-12 2002-12-31 Mayo Foundation For Medical Education And Research Marker for inflammatory conditions
CN1266478C (zh) * 2003-06-05 2006-07-26 马旭 用胰岛素生长因子结合蛋白－4水解酶检测急性冠状动脉综合征的试剂盒
WO2006086891A1 (en) * 2005-02-18 2006-08-24 National Research Council Of Canada Insulin-like growth factor binding protein-4 compounds and methods for inhibiting angiogenesis and tumor growth in mammalian cells
US20070190580A1 (en) * 2005-10-31 2007-08-16 Beckman Coulter, Inc. Immunoassay of Fragments of Insulin-Like Growth Factor Binding Proteins
JP5201822B2 (ja) * 2006-12-11 2013-06-05 アボット・ラボラトリーズ ガストリン放出ペプチド前駆体の免疫学的測定方法
CN101206225A (zh) * 2006-12-19 2008-06-25 天津天美生物技术有限公司 化学发光免疫分析检测心肌钙蛋白t的方法
EP2498095A3 (en) * 2007-01-25 2012-11-28 Roche Diagniostics GmbH Use of IGFBP-7 in the assessment of heart failure
FI20095733A0 (fi) 2009-06-29 2009-06-29 Hytest Oy IGFBP-4-fragmenttien määrittäminen diagnostisena menetelmänä

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2719914C1 (ru) * 2019-12-06 2020-04-23 федеральное государственное бюджетное образовательное учреждение высшего образования "Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации Способ прогнозирования исходов операций коронарного шунтирования

Also Published As

Publication number Publication date
EP2697654B1 (en) 2020-05-27
JP2014515824A (ja) 2014-07-03
EP2697654A4 (en) 2014-11-12
CN103703373A (zh) 2014-04-02
US10191066B2 (en) 2019-01-29
WO2012140327A1 (en) 2012-10-18
US20140017714A1 (en) 2014-01-16
EP2697654A1 (en) 2014-02-19
KR20140030188A (ko) 2014-03-11

Similar Documents

Publication Publication Date Title
IN2015DN01767A (fi)
MX2020001227A (es) Composiciones y metodos para detectar y cuantificar la proteina en la celula hospedera en las lineas de celulas y productos de polipeptidos recombinantes.
FI20115367A0 (fi) Menetelmä sydän- ja verisuonitapahtumien määrittämiseksi käyttämällä IGFBP-fragmentteja
EP3590959A3 (en) Pathology biomarker assay
GB201111361D0 (en) Biochemical markers for neurodegenerative conditions
IN2012DN03911A (fi)
EP2829881A3 (en) Diagnostic for colorectal cancer
PH12015502849B1 (en) Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers
GB201106548D0 (en) A method for determining ligand binding to a target protein using a thermal shift assahy
MX337535B (es) Anticuerpo, kit y metodo para la determinacion de peptidos amiloides.
WO2013159872A8 (en) Biomarkers for the diagnosis, prognosis, assessment and therapy stratification of syncope
PL2183599T3 (pl) Wysoko specyficzny test immunologiczny i zestaw do oznaczania peptydów i białek o znaczeniu biologicznym
MX357429B (es) Predictores para el tratamiento del cáncer.
WO2015014794A8 (en) Use of alpha-crystallin b (cryab) in the assessment of heart failure
WO2012122334A3 (en) Procollagen carboxy-terminal propeptides as a target and treatment for angiogenesis related diseases
MX343630B (es) Medios y metodos para diagnosticar y tratar esclerosis multiple.
WO2012137180A3 (en) Biomarkers of immunotherapy efficacy
WO2012122094A3 (en) Biomarkers of cardiac ischemia
PE20120592A1 (es) Metodo con biomarcadores para el seguimiento de un tratamiento
GB201111788D0 (en) In vitro assessment of cardiovascular events by assay for neo-epitopes
MX2015015023A (es) Metodo para la determinacion de cobre libre.
RU2018138055A (ru) Способ прогнозирования риска возникновения рака или диагностирования рака у женщины
ES2650733T3 (es) Anticuerpo específico para el dominio C-terminal de la profilagrina y su uso
ATE525478T1 (de) Serumbiomarker für morbus chagas
ATE359516T1 (de) Verwendung des proteins crabp ii (cellular retinoic acid-binding protein ii) als marker für brustkrebs

Legal Events

Date Code Title Description
FD Application lapsed